Through its U.S. subsidiary, Milla Pharmaceuticals Inc., A.forall announced the direct commercialization and launch of Sodium Acetate Injection 2mEq/mL in 20mL, 50mL, and 100mL vials.

Sodium Acetate Injection, USP is indicated as a source of sodium for addition to large volume intravenous fluids to prevent or correct hyponatremia in patients with restricted or no oral intake. It is also useful as an additive for preparing specific intravenous fluid formulas when the needs of the patient cannot be met by standard electrolyte or nutrient solutions.

“We continue supplying Sodium Acetate in the U.S. throughout this time of shortage as we have been doing over the last four years, but we are now proudly addressing the shortage directly. Thanks to our own commercial organization, we are now able to provide U.S. patients with the medicines they need most in an even more efficient way.

“This important milestone represents the company’s continued investment in and increasing internal dedication to serving the U.S. marketplace, especially for products which have been or continue to be reported in shortage,” commented Erik Lazarich, A.forall’s President of U.S. Operations.

Please see link for Full Prescribing Information.

About A.forall & Milla Pharmaceuticals

At A.forall, our mission is all about Making Affordable Medicines Available To All: we develop value-added generic pharmaceuticals, solve product shortages and fill unmet medical needs so that patients can continue their treatment. At the same time, we are reducing costs to the healthcare system and increasing customer convenience for a more sustainable world.

Milla Pharmaceuticals Inc., the U.S. subsidiary of A.forall, is engaged in the development, licensing, acquisition, and commercialization of generic prescription drugs for the U.S. market, focusing on niche injectable and solution products for hospitals and clinics.

More info: About – A.forall & About - Milla Pharmaceuticals

View source version on businesswire.com: https://www.businesswire.com/news/home/20250722981335/en/

Milla Pharmaceuticals Inc. announced the direct commercialization and launch of Sodium Acetate Injection 2mEq/mL in 20mL, 50mL, and 100mL vials.